Pharmaceutical companies have discovered false data from clinical trial sites that invalidate their studies aimed at treating Alzheimer's disease.[1] BioVie claims 15 testing sites in South Florida provided questionable data about its experimental drug NE3107, including impossible improvements in cognitive function in patients in the placebo group and copied brain images between patient records.[1] Annovis found that test sites offered financial incentives and food to attract participants, with many people feigning cognitive impairment to qualify for the studies, including women who were simultaneously participating in multiple clinical trials without authorization.[1] Bristol Myers Squibb announced that irregularities in the conduct of clinical trials at some sites led to the exclusion of data for its drug Cobenfy and the need to enroll new patients.[1] Test City denies the allegations and is seeking dismissal of the lawsuits, saying the claims are "incomplete, legally flawed and without merit".[1] These cases highlight a serious problem with data integrity in Alzheimer's clinical trials.